ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1466

Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: A Correlative Study of Non-Invasive Arterial Health Testing with the Inflammatory Burden of Disease

Erin Scanlon1, Rekha Mankad2, Cynthia S. Crowson3, Iftikhar Kullo4, Sharon Mulvagh2, Eric L. Matteson1, Zoran Kvrgic1 and John M. Davis III5, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Atherosclerosis, Cardiovascular disease and rheumatoid arthritis (RA), Health Assessment Questionnaire

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Persons with rheumatoid arthritis (RA) have increased morbidity and mortality attributable to atherosclerotic cardiovascular disease (ASCVD) events. It is unknown how presence of subclinical ASCVD, as measured by arterial health parameters, is affected by the current state of RA disease activity. The objective of this study was to determine the relationship between non-invasive arterial health measures and measures of both current and average disease activity over time in patients with established RA.

Methods:   50 patients with RA underwent non-invasive arterial health testing (measures of arterial stiffness: corrected aortic augmentation index; pulse wave velocity) and rheumatologic assessment of clinical disease activity (tender/swollen joint counts; the Clinical Disease Activity Index (CDAI); the Health Assessment Questionnaire (HAQ) disability index). Clinical measures of disease activity during 3 years prior to the study visit were averaged to obtain time-averaged measures. The AHA/ACC Pooled Cohort Equation (estimated 10-year CV risk %) was used to classify patients as low/intermediate/high risk. Spearman methods were used to determine the correlation between the rheumatologic disease activity scores and arterial health testing parameters.

Results:   In the 50 patients (mean age: 57.5 years; 76% female, mean RA disease duration: 6.4 years), the disease activity was moderate, with mean (±SD) CDAI of 16.9 (15.3). At the study visit, the corrected aortic augmentation index correlated with the CDAI (r=0.37, p=0.009) and the HAQ (r=0.33, p=0.019). The corrected aortic augmentation index correlated with time-averaged measures of the tender joint count (r=0.37, p= 0.008); CDAI (r=0.36, p=0.01); HAQ (r=0.36, p=0.009); swollen joint count (r=0.36, p =0.01); patient global assessment (r=0.33, p=0.02); physician global assessment (r=0.35, p=0.014); and pain score (r=0.38, p=0.007). Marginally significant correlations emerged between the aortic pulse wave velocity and the time-averaged CDAI (r=0.26, p=0.07); tender joint count (r=0.26, p=0.07); and physician global assessment (r=0.28, p=0.05). Adjusted correlations between time-averaged CDAI and corrected aortic augmentation showed statistical significance (r=0.41, p=0.007) when adjusted for the pooled cohort CV risk score, and marginal significance when adjusted for the pooled cohort CV risk score and use of prednisone, methotrexate and/or biologics (r=0.3, p=0.07).

Conclusion:   The results demonstrate that measures of arterial stiffness, especially the corrected aortic augmentation index, correlate with the time-averaged burden of disease activity as well as current disease activity. The findings suggest that non-invasive arterial health testing provides a means to measure the effects of inflammatory disease burden on arterial function even after accounting for estimated CV risk scores.


Disclosure: E. Scanlon, None; R. Mankad, None; C. S. Crowson, None; I. Kullo, None; S. Mulvagh, None; E. L. Matteson, Regeron, 2,Amgen, 2,Celgene, 2,Genentech and Biogen IDEC Inc., 2,Mesoblast, 2,Pfizer Inc, 2,Novartis Pharmaceutical Corporation, 2,Roche Pharmaceuticals, 2,Glaxo Smith Kline, 2,Up-To-Date, 9; Z. Kvrgic, None; J. M. Davis III, Pfizer Inc, 2,Genentech and Biogen IDEC Inc., 2.

To cite this abstract in AMA style:

Scanlon E, Mankad R, Crowson CS, Kullo I, Mulvagh S, Matteson EL, Kvrgic Z, Davis JM III. Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: A Correlative Study of Non-Invasive Arterial Health Testing with the Inflammatory Burden of Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-assessment-in-persons-with-rheumatoid-arthritis-a-correlative-study-of-non-invasive-arterial-health-testing-with-the-inflammatory-burden-of-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-assessment-in-persons-with-rheumatoid-arthritis-a-correlative-study-of-non-invasive-arterial-health-testing-with-the-inflammatory-burden-of-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology